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of ﬁbrosis). Interestingly, in this carefully followed Span-
ish cohort, histological progression was clearly halted by
UDCA treatment in comparison to placebo [6].
In contrast to this high-quality randomized, placebo-
controlled trial, meta-analyses which include trials with a
duration of up to two years for a disease with an esti-
mated duration of up to two decades may be suited to
analyze short-term biochemical eﬀects of medical treat-
ment, but certainly carry the risk of diluting the informa-
tion needed for a well-based long-term survival analysis.
The attempts of others [7,8] to provide meta-analyses
which included long-term randomized, placebo-con-
trolled trials for survival analysis only to avoid this dilu-
tive eﬀect may deserve mentioning here; these authors [7]
concluded that long-term treatment with mid-dose
UDCA can improve liver biochemistry, delay histologi-
cal progression in early-stage disease and improve sur-
vival-free of liver transplantation. We have to keep in
mind that meta-analyses are only as good as the trials
they include and have to be judged with some caution [9].
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but indirect comparisons should be avoidedTo the Editor:
In their recent paper Buti and colleagues [1] claim to
have performed a “cost-eﬀectiveness analysis of diﬀerent
oral antiviral therapies in patients with chronic hepatitis
B”, but they did so presenting credible results in an inap-
propriate and potentially misleading manner.
By deﬁnition incremental cost-eﬀectiveness ratio re-
lates to incremental eﬀectiveness put in relation to incre-
mental cost. Therefore, the natural referent alternative
for “oral antiviral therapies” is a therapy in which no
antiviral therapy is used, what Buti and colleagues refer
to as “no treatment”. Indeed Buti and colleagues [1] con-
ceptually appraised decremental, rather than incremental,
cost-eﬀectiveness ratio, by unconventionally taking as a
reference the point estimate “most eﬃcacious treat-
ment”. This is not a standard procedure in cost-eﬀective-
ness analyses. Consequently, the study would be much
more informative presenting the incremental cost of
(each) antiviral therapy compared to “no treatment” inrelation to its incremental eﬀectiveness. This is the stan-
dard approach widely adopted by public health technol-
ogy assessment agencies. This approach has several
advantages: (1) it informs decision makers on ICER
(Incremental Cost-Eﬀectiveness Ratio) of the various
technologies, individually, that can be used compared
to no treatment; (2) it does not require the use of a
sophisticated model that would be needed to detect a
meaningful and signiﬁcant diﬀerence between active
treatments; (3) it does not require problematic and
sophisticated adjustments for diﬀerential characteristics
of patients included in RCT’s (Randomized Clinical
Trial) of diﬀerent active treatments (e.g. diﬀerent base-
line viral load, diﬀerences in tolerability proﬁle), which
are required when (indirect) comparisons between active
treatments are made. A careful reading of the paper by
Buti and colleagues [1] conﬁrms that the model seems
to make accurate and discriminating predictions of costs
and outcomes when “no treatment” on one side and
“oral antiviral treatment” on the other side are consid-
ered. Ultimately the authors evaluated the eﬃcacy of ten-
ofovir vs. all other drugs as the diﬀerences between
response rates obtained from diﬀerent trials. However
when diﬀerent treatments are studied in separate trials
actual diﬀerences between response rates associated with
the treatments (treatment eﬀect) are confounded by the
diﬀerences between the trials (trial eﬀect), thus it is
impossible to estimate the eﬀects separately. Typically,
trial eﬀects are due to diﬀerent patients characteristics
(e.g. baseline, viral load). With regard to the cost of ther-
apy used in the model it seems that only the cost of drugs
was considered without considering the additional cost
due to the administration cost, toxicity (e.g. monitoring
of renal function for tenofovir) management of side-ef-
fects etc. Consequently, the model does not seem sensi-
tive and precise enough for the purpose of comparing
active treatments one against the other (see Table 1).
True and appropriate incremental cost per QALY
(Quality Adjusted Life Year) gained of each individual
oral antiviral therapy compared to “no treatment” can
be computed, which are based on the very data of Buti
and colleagues [1].
Once this standard approach for computing ICER is
used, one can observe that all oral antiviral therapies are
cost-eﬀective compared to “no treatment”, far below the
commonly agreed threshold of 50.000 Euro per QALY.
This is reassuring for the decision makers that oral anti-
viral therapies are value for money, so that the decision
on appropriate therapy for the next patient can safely re-
turn in the sphere of clinical judgment and physician–
patient interaction.
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Some oral antivirals are more cost-eﬀective than others for
the treatment of chronic hepatitis B
To the Editor:
In their letter referring to our study “Modeling the
cost-eﬀectiveness of diﬀerent oral antiviral therapies in
patients with chronic hepatitis B”, Mantovani and de
Portu claim that the presentation of our results is inap-
propriate. We beg to disagree.
Table 1
ICER of each active treatment vs. no treatment.
Cost QALY Incremental cost Incremental QALY ICERa
HBeAg positive pts
No treatment 83,406 13.69 Reference Reference
Telbivudine 90,721 14.96 7315 1.27 5760
Entecavir 90,273 15.21 6867 1.52 4518
Adefovir 91,199 14.68 7793 0.99 7872
Lamivudine 87,134 14.67 3728 0.98 3804
Tenofovir 87,615 15.43 4209 1.74 2419
HBeAg negative pts
No treatment 90,866 12.48 Reference Reference
Telbivudine 111,097 15.47 20,231 2.99 6766
Entecavir 114,968 16.11 24,102 3.63 6640
Adefovir 103,916 14.21 13,050 1.73 7543
Lamivudine 95,547 14.30 4681 1.82 2572
Tenofovir 105,889 16.28 15,023 3.8 3953
Bold value represents the higher and lowest value in the group.
Abbreviations: RCT, Randomized Clinical Trial; QALY, Quality Adjusted Life Year; ICER, Incremental Cost-Eﬀectiveness Ratio.
a Incremental cost per incremental QALY. All costs are in Euro.
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